Cartesian Therapeutics, Inc. – NASDAQ:RNAC
Cartesian Therapeutics stock price today
$11.06
-8.72
-44.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Cartesian Therapeutics stock price monthly change
+11.56%
month
Cartesian Therapeutics stock price quarterly change
+11.56%
quarter
Cartesian Therapeutics key metrics
Market Cap | 489.03M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -48.9 |
Revenue | 25.90M |
EBITDA | -79.82M |
Income | -254.87M |
Revenue Q/Q | -1.65% |
Revenue Y/Y | -68.68% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -308.14% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCartesian Therapeutics stock price history
Cartesian Therapeutics stock forecast
Cartesian Therapeutics financial statements
| Jun 2023 | 5.24M | -11.38M | -216.94% |
|---|---|---|---|
| Sep 2023 | 6.55M | -9.00M | -137.41% |
| Dec 2023 | 8.26M | -177.65M | -2149.26% |
| Mar 2024 | 5.84M | -56.82M | -973.01% |
| Dec 2023 | 8.26M | -177.65M | -2149.26% |
|---|---|---|---|
| Mar 2024 | 5.84M | -56.82M | -973.01% |
| Sep 2025 | 9.51M | -9.88M | -103.89% |
| Dec 2025 | 10.31M | -9.88M | -95.78% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 139506000 | 74.05M | 53.09% |
|---|---|---|---|
| Sep 2023 | 106034000 | 45.70M | 43.1% |
| Dec 2023 | 305050000 | 745.23M | 244.3% |
| Mar 2024 | 325207000 | 442.00M | 135.92% |
| Jun 2023 | -9.89M | -12K | -2.58M |
|---|---|---|---|
| Sep 2023 | -9.21M | 0 | -24.78M |
| Dec 2023 | -23.28M | 6.49M | 14.08M |
| Mar 2024 | -15.91M | -602K | 43.03M |
Cartesian Therapeutics alternative data
| Feb 2024 | 64 |
|---|---|
| Mar 2024 | 37 |
| Apr 2024 | 37 |
| Jun 2024 | 37 |
| Jul 2024 | 37 |
Cartesian Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 800 | 0 |
| Feb 2024 | 3200 | 0 |
| Mar 2024 | 1219316 | 0 |
| Aug 2024 | 15516 | 0 |
| Oct 2024 | 205721 | 0 |
| Nov 2024 | 431940 | 228172 |
| Dec 2024 | 52189 | 13664 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SPRINGER TIMOTHY A director, 10 perc.. | Common Stock | 5,181 | $19 | $98,439 | ||
Purchase | SPRINGER TIMOTHY A director, 10 perc.. | Common Stock | 21,800 | $18.94 | $412,979 | ||
Purchase | SPRINGER TIMOTHY A director, 10 perc.. | Common Stock | 3,376 | $18.93 | $63,901 | ||
Purchase | SPRINGER TIMOTHY A director, 10 perc.. | Common Stock | 10,529 | $18.35 | $193,207 | ||
Purchase | SPRINGER TIMOTHY A director, 10 perc.. | Common Stock | 11,303 | $17.39 | $196,514 | ||
Option | KURTOGLU METIN officer: Chief Technology Officer | Stock Option (Right to Buy) | 2,901 | $1.41 | $4,090 | ||
Option | KURTOGLU METIN officer: Chief Technology Officer | Common Stock | 2,901 | $1.41 | $4,090 | ||
Sale | KURTOGLU METIN officer: Chief Technology Officer | Common Stock | 2,901 | $24.35 | $70,639 | ||
Option | KURTOGLU METIN officer: Chief Technology Officer | Stock Option (Right to Buy) | 10,763 | $1.41 | $15,176 | ||
Option | KURTOGLU METIN officer: Chief Technology Officer | Common Stock | 10,763 | $1.41 | $15,176 |
-
What's the price of Cartesian Therapeutics stock today?
One share of Cartesian Therapeutics stock can currently be purchased for approximately $11.06.
-
When is Cartesian Therapeutics's next earnings date?
Unfortunately, Cartesian Therapeutics's (RNAC) next earnings date is currently unknown.
-
Does Cartesian Therapeutics pay dividends?
No, Cartesian Therapeutics does not pay dividends.
-
How much money does Cartesian Therapeutics make?
Cartesian Therapeutics has a market capitalization of 489.03M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 76.53% to 26M US dollars.
-
What is Cartesian Therapeutics's stock symbol?
Cartesian Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "RNAC".
-
What is Cartesian Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cartesian Therapeutics?
Shares of Cartesian Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Cartesian Therapeutics have?
As Jul 2024, Cartesian Therapeutics employs 37 workers.
-
When Cartesian Therapeutics went public?
Cartesian Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 22 Jun 2016.
-
What is Cartesian Therapeutics's official website?
The official website for Cartesian Therapeutics is selectabio.com.
-
Where are Cartesian Therapeutics's headquarters?
Cartesian Therapeutics is headquartered at 65 Grove Street, Watertown, MA.
-
How can i contact Cartesian Therapeutics?
Cartesian Therapeutics's mailing address is 65 Grove Street, Watertown, MA and company can be reached via phone at +61 79231400.
Cartesian Therapeutics company profile:
Cartesian Therapeutics, Inc.
selectabio.comExchange:
NASDAQ
Full time employees:
37
Industry:
Biotechnology
Sector:
Healthcare
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
65 Grove Street
Watertown, MA 02472
Watertown, MA 02472
CIK: 0001453687
ISIN: US8162123025
:
